Dennis McWilliams
Managing Director @ Sante Ventures
Austin, United States
Dennis McWilliams is a Partner at Sante Ventures.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries Dennis McWilliams invests in
Stages Dennis McWilliams invests in
Countries Dennis McWilliams invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (42%)
- Medical 4 (33%)
- Biotechnology 3 (25%)
- Artificial Intelligence 3 (25%)
- Software 2 (17%)
Stage
- Series A 8 (67%)
- Seed 2 (17%)
- Series B 1 (8%)
Country
- United States 7 (58%)
- Japan 1 (8%)
- Canada 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M / Series B / Jul 16, 2026 | ||
|
SONIRE Therapeutics
|
SONIRE Therapeutics is a clinical-stage medical device company. It is a U.S. subsidiary of SONIRE Therapeutics Co., Ltd.. | $18M / Series A / Apr 15, 2026 | |
| SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $18M / Series A / Apr 15, 2026 | ||
| OutcomesAI operates as a healthcare company, that combines AI Voice Agents with licensed nurses to deliver safe, scalable care across health systems. | $10M / Seed / Oct 14, 2025 | ||
| BeeKeeperAI is a zero trust collaboration platform protecting both algorithm IP and regulated data. | $12.1M / Series A / Jun 27, 2023 | ||
| Surgical Safety Technologies delivers data-driven AI technology to hospitals for safe surgeries. It empowers surgeons with an objective assessment of technical and non-technical proficiency using academically validated frameworks. | $15M / Series A / May 04, 2023 | ||
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $10.6M / Series A / Aug 31, 2022 | ||
| RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $15M / Series A / Jun 23, 2021 | ||
| Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncologyas well as autoimmune diseases. | $16.5M / Series A / Jan 26, 2021 | ||
| KelaHealth Surgical Intelligence Platform delivers patient-specific predictive insights and recommended interventions at key decision points to improve surgical care quality and clinical operations. It is creating a learning ecosystem to improve surgical care outcomes. | $2.9M / Seed / Oct 28, 2020 | ||
| See all 12 investments → | |||
Co-Investors
About Sante Ventures
Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has nearly $1 billion in capital under management.
Sante Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jason Brandt
Chief Financial Officer & Chief Compliance Officer
|
|||
|
Auriel August
Principal
|
|||
Casey Cunningham
Partner & Chief Scientific Officer
|
|||
David Kaufman
Chief Operating Officer
|
|||
|
Dennis McWilliams
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dennis McWilliams invest in?
Dennis McWilliams invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dennis McWilliams?
Public channels for Dennis McWilliams include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dennis McWilliams last invest?
The most recent investment recorded for Dennis McWilliams closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
